Background Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is an autoimmune condition with significant morbidity and mortality. Methods A retrospective review was performed at a single institution. All patients admitted to the LAC + USC burn unit from May 1st 2015–January 1st 2018 with a histologic diagnosis of SJS/TEN were reviewed. Patient characteristics and outcomes were recorded. These outcomes were compared to our previously published cohort. Results Thirteen total consecutive SJS/TEN patients were treated with etanercept. Compared to non-etanercept treated patients, etanercept-treated patients did not experience a significant difference in mortality (15.4% vs. 10%, P = 0.58), ICU days (6.9 vs. 15.1, P = 0.08), length-of-stay (9.8 vs 16.4, P = 0.11), or infections (38.5% vs. 57.5%, P = 0.58). The standardized mortality ratio in etanercept-treated patients was 0.44 (95% CI, 0.21, 0.65). In general, etanercept-treated patients had higher SCORTENs (3 vs. 2, P = 0.03) and longer delays to presentation (5.2 vs. 2.7 days, P Conclusions Etanercept can be considered in the treatment of SJS/TEN patients in addition to IVIg, and supportive care in a burn unit.
Full Text via ClinicalKey